Navigation Links
Nephros Announces $3.2 Million Financing Through Completion of Rights Offering and Private Placement Transactions
Date:3/4/2011

RIVER EDGE, N.J., March 4, 2011 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced the completion of its rights offering and private placement that together will result in gross proceeds of approximately $3.2 million to Nephros.

"Nephros is pleased to have successfully completed its shareholders rights offering and related private placement financing," said James S. Scibetta, Chairman of Nephros.  "The proceeds from these transactions will provide Nephros with funds to pursue the further development and commercialization of our filtration products."

Nephros' stockholders subscribed for 99,297,082 units in its previously announced rights offering and Nephros accepted all basic subscription rights and oversubscription privileges.  The subscription period for the rights offering expired at 5:00 p.m. Eastern Time on March 3, 2011.  Gross proceeds to Nephros from the sale of these units in the rights offering will be approximately $2.0 million.

Under the terms of the rights offering, Nephros distributed at no charge non-transferable subscription rights to purchase up to an aggregate of 175,000,000 units to stockholders who owned shares of Nephros common stock as of the close of business on January 31, 2011, which was the record date for the rights offering.  Each subscription right entitled the holder to purchase 4.185496618 units at a subscription price of $0.02 per unit.  Each unit consists of one share of common stock and a warrant to purchase 0.924532845 shares of common stock at an exercise price of $0.02 per share for a period of five years following the issue date of the warrant.  Based on the results of the rights offering, Nephros will issue an aggregate of 99,
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nephros Extends Rights Offering
2. Nephros Has Commenced Rights Offering
3. Nephros Rights Offering Registration Statement Declared Effective
4. Nephros Reports 2010 Third Quarter Financial Results
5. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
6. Nephros Reports 2010 Second Quarter Financial Results
7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
8. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
9. Nephros Reports 2010 First Quarter Financial Results
10. Nephros Signs Development Agreement with STERIS
11. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
(Date:7/24/2014)...  The American Association for Homecare (AAHomecare) yesterday ... help address audit issues in the HME industry ... the information technology lead in shaping its HME ... billing and business management solutions for nearly 3,000 ... support this important initiative on behalf of all ...
(Date:7/24/2014)... , July 24, 2014 Decision Resources Group ... the EU5 countries ( France , ... Spain and the ... of the first once-daily long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) ... uptake of Relvar as a first-line LABA/ICS FDC in ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3
... Calif., Nov. 17 Poniard Pharmaceuticals, Inc. (Nasdaq: ... randomized, controlled Phase 2 trial of picoplatin in patients ... indicated that picoplatin, given once every four weeks in ... has comparable efficacy to oxaliplatin, given in combination with ...
... , LAKE ZURICH, Ill., Nov. 17 ... improving blood collection, separation, safety and availability, announced today ... the Verax Platelet PGD® test as a quality control ... platelets prior to transfusion. Fenwal is the exclusive ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 2FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 3FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 4
(Date:7/24/2014)... BUFFALO, N.Y. Primary care treatment of overweight and ... and child compared to when only the child is ... Pediatrics and conducted at the University at Buffalo ... in this study were overweight or obese and had ... was overweight or obese, according to body mass index ...
(Date:7/24/2014)... caffeine may worsen the hot flashes and night sweats ... through menopause, new survey data suggests. "While these ... intake may be useful for those postmenopausal women who ... Dr. Stephanie Faubion, director of the Women,s Health Clinic ... caffeine -- a stimulant found in coffee and colas ...
(Date:7/24/2014)... 24, 2014 A new study led by the ... interplay among bacteria, viruses and the immune system during ... their potential to infect others based on ... amounts of virus in their semen despite having low ... different levels of the virus can be found in ...
(Date:7/24/2014)... July 24, 2014 Memantine was initially developed ... marketed in Germany under the brand name Akatinol; it was ... as Ebixa and in the USA to Forest Labs as ... million in 2013. In the US, Forest reported Namenda sales ... expiry in Canada, Australia and the European region has increased ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Members of the ... Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, as ... appointed him to the Board and that his peers chose ... want to provide the best I can for the citizens ... am uniquely positioned to provide a special insight to concerns ...
Breaking Medicine News(10 mins):Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... contrast to normal cells, which only divide a finite number ... growth arrest or simply die, cancer cells never cease to ... have uncovered an important clue to one of the mechanisms ... April 22, 2011 issue of Molecular Cell , reveal ...
... -- A new poll finds that almost all parents of ... get exercise during each school day. However, one-third said their ... survey findings come at a time when U.S. schools continue ... Obesity is thought to affect one out of every six ...
... Monitoring Committee (DSMC) has determined that patients in a ... a standard chemotherapy regimen for advanced prostate cancer did ... patients on the same chemotherapy regimen who got a ... had advanced, hormone-refractory prostate cancer were given up to ...
... a high school athlete drops dead, the rare but ... For reasons that remain a mystery to scientists, some ... experience an unusual heart arrhythmia. With over-exertion, their hearts ... now, screening for the hard-to-detect syndrome has been prohibitively ...
... the worm is shedding light on a protein associated with ... a highly targeted way to treat them. University ... which is present in many cell types but whose exact ... protein controls key aspects of the movement, or secretion, of ...
... Even people who show a clear treatment ... like insomnia, sadness and decreased concentration, researchers at ... data from the largest study on the treatment ... working overall, missed these symptoms. If patients have ...
Cached Medicine News:Health News:A new ending to an old 'tail' 2Health News:A new ending to an old 'tail' 3Health News:U.S. Parents Want Kids More Active During School Day: Poll 2Health News:Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer 2Health News:Standing up for athletes at risk 2Health News:Worm studies shed light on human cancers 2Health News:Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find 2Health News:Antidepressants may not improve all symptoms of depression, UT Southwestern researchers find 3
... The THERMOstar is a high performance temperature ... microplates. Temperature, shaking speed and incubation time ... the status parameters are displayed on the ... above and below the microplates provide uniform ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9 Broth...
An agent used for making solid microbiological media....
Medicine Products: